AbbVie’s Technivie gets FDA approval to treat genotype 4 chronic hepatitis C
Technivie is an all-oral, interferon-free, direct-acting antiviral treatment consisting of the fixed-dose combination of paritaprevir/ritonavir (150/100mg) co-formulated with ombitasvir (25mg) dosed once daily and taken with a meal,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.